Drug Database
BE

bevacizumab (Abevmy / bevacizumab, Biocon / Krabeva)

✓ Approved

Mylan · VEGFA · Monoclonal Antibodies

What is bevacizumab?

bevacizumab is a monoclonal antibodies developed by Mylan. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAbevmy, bevacizumab, Biocon, Krabeva
CompanyMylan
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetVEGFA
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Mylan

Mechanism of Action

Molecular Targets

bevacizumab acts on 1 molecular target:

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

bevacizumab is developed for 9 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Brain neoplasm malignant✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Fallopian tube cancer✓ Approved

+4 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedJournal of pharmaceutical health care and sciences2026-07-17

Early-onset duodenal perforation during bevacizumab-containing chemotherapy in a patient with ovarian cancer: a case report.

Nagase Satoshi S, Taguchi Keisuke K, Yoshida Takanori T, Matsumoto Shokei S et al.

Bevacizumab-induced gastrointestinal perforation is a potentially fatal adverse event. However, duodenal perforations are rare. Conversely, patients with cancer often have concomitant rheumatoid arthritis and may be treated with a combination of anti-rheumatic drugs and symptomatic medications; however, the effects of these concomitant medications on bevacizumab-related perforation remain understudied. This report describes the case of a patient with ovarian cancer and a history of anti-rheumatic drug treatment who developed early-onset duodenal perforation during bevacizumab-containing chemotherapy, highlighting the importance of assessing the risk of duodenal perforation and the provision of multidisciplinary management. The patient was a woman in her 50s with ovarian cancer that metastasized to the para-aortic lymph nodes. She was diagnosed with platinum-sensitive recurrence, and combination therapy with gemcitabine, carboplatin, and bevacizumab was initiated. She was also taking iguratimod and methotrexate for rheumatoid arthritis treatment. The patient developed sudden abdominal pain during the second course of chemotherapy and presented to the emergency department. A computed tomography (CT) scan revealed free gas, raising the suspicion of gastrointestinal perforation. Emergency laparotomy confirmed a duodenal perforation that was surgically covered with the ligamentum teres hepatis. A perforation of <1 cm was found in the anterior wall of the duodenal bulb, but the postoperative course was uneventful. The patient was discharged on postoperative day 7 and continued chemotherapy without bevacizumab. Postoperative upper endoscopy revealed an H2 stage ulcer. When administering bevacizumab to patients with ovarian cancer and multiple perforation risk factors, careful consideration should be given to evaluating existing ulcers, appropriately using concomitant medications, and modifying perforation risk factors to avoid serious adverse events. Therefore, collaboration between a multidisciplinary team, including oncologists, rheumatologists, and pharmacists, is crucial for appropriate drug use and continuous monitoring.

PMID 42464367
Read full article →
PubMedAnnals of surgical oncology2026-07-17

Integrated Evaluation of Survival, Surgical Conversion, and Toxicity for Induction Therapy in Initially Unresectable Colorectal Liver Metastases: An Individual Patient Data Network Meta-analysis.

Nie Guilin G, Li Xinming X, Wang Yaoqun Y, Xu Jianrong J et al.

Patients with initially unresectable colorectal cancer liver metastases (CRLM) could derive benefits from active induction regimens by increasing the likelihood of surgical conversion. However, the comparative benefit-risk profiles of currently available regimens remain unclear. We performed an individual patient data (IPD) and network meta-analysis (NMA) to compare the efficacy of active induction regimens. IPD was reconstructed from randomized controlled trials (RCTs). The primary outcome was progression-free survival (PFS). Secondary outcomes included R0-1 resection rate, overall survival (OS), and grade ≥ 3 adverse events (AEs). Subgroup analyses were conducted according to KRAS/BRAF status and primary tumor sidedness. An entropy-weighted TOPSIS model was used to integrate efficacy and safety outcomes. Seven RCTs involving 1368 patients were included. IPD-based network analysis suggested that bevacizumab + triplet-chemotherapy was associated with the highest probability of improving R0-1 resection rate (0.99) and prolonging PFS (0.99). No significant differences in OS were observed among targeted therapy-based regimens. For patients with KRAS/BRAF wild-type tumors, cetuximab + doublet-chemotherapy is the only therapy performed better than chemotherapy in prolonging PFS. Bevacizumab + triplet-chemotherapy demonstrated superior efficacy among patients with KRAS/BRAF-mutant tumors. No significant PFS differences were observed among therapies in both left-sided and right-sided. Bevacizumab + doublet-chemotherapy demonstrated a more balanced benefit-risk profile with the highest Topsis scores (0.67). Bevacizumab plus triplet chemotherapy improves disease control and surgical conversion benefits but is associated with greater toxicity. Bevacizumab plus doublet chemotherapy showed the most favorable benefit-risk balance and may represent an optimal compromise for patients with initially unresectable CRLM.

PMID 42463606
Read full article →
PubMedRespirology case reports2026-07-17

Treatment-Emergent Isolated EGFR C797S Mutation Following First-Line Osimertinib-Based Combination Therapy: A Case Report and Literature Review.

Nguyen Thu Huong TH, Nguyen Hoang Gia HG, Le Thu Ha TH

Osimertinib is the standard first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC), although acquired resistance remains inevitable. The EGFR C797S mutation is a recognized on-target resistance mechanism; however, the T790M-negative/C797S-only subtype following frontline osimertinib-based combination therapy is rarely reported. We describe a 44-year-old Vietnamese never-smoking woman diagnosed with stage IV lung adenocarcinoma harbouring EGFR exon 21 L858R mutation. First-line treatment with pemetrexed-carboplatin plus osimertinib achieved a near-complete response, followed by maintenance osimertinib monotherapy. After 26 months of disease control, radiologic progression occurred with recurrent bilateral pulmonary metastases and right supraclavicular lymphadenopathy. Repeat biopsy and next-generation sequencing identified persistent EGFR L858R (VAF 13.92%) and acquired EGFR C797S (VAF 6.19%) without detectable T790M, consistent with a C797S-only resistance profile. Subsequent gefitinib plus bevacizumab therapy produced a rapid radiologic response with near-complete resolution of contralateral pulmonary lesions, suggesting retained sensitivity to reversible EGFR tyrosine kinase inhibitor-based therapy in C797S-only disease.

PMID 42466433
Read full article →
PubMedDiscover oncology2026-07-17

Mechanistic synergies and optimal sequencing of anti‑VEGF plus immune checkpoint inhibition in gastrointestinal cancers.

Lorestani Parsa P, Robat-Jazi Behrouz B, Nejati Negar N, Jazi Kimia K et al.

Gastrointestinal (GI) malignancies remain leading causes of cancer-related mortality despite advances in therapeutic strategies. This review was undertaken to provide a comprehensive synthesis of the mechanistic rationale, preclinical evidence, and clinical data supporting the combination of anti-vascular endothelial growth factor (anti-VEGF) agents with immune checkpoint inhibitors (ICIs) in GI cancers, with particular emphasis on optimal sequencing strategies and unresolved challenges. We performed a narrative review of the literature, integrating preclinical studies on tumor microenvironment (TME) dynamics with key phase II/III clinical trials across hepatocellular carcinoma (HCC), colorectal cancer (CRC), gastric/gastroesophageal junction cancers, pancreatic ductal adenocarcinoma, and other GI malignancies. The core rationale for this combination stems from complementary mechanisms: anti-VEGF therapy induces vascular normalization, enhances immune cell infiltration, and reduces immunosuppression within the TME, thereby converting immunologically "cold" tumors into "hot" tumors that are more responsive to checkpoint blockade. Clinically, the strongest evidence comes from the IMbrave150 trial, which established atezolizumab plus bevacizumab as the new first-line standard of care in advanced HCC, with promising signals also emerging in colorectal and gastric cancers (GC). Nevertheless, significant limitations persist, including overlapping toxicities, adaptive resistance mechanisms, and the lack of validated predictive biomarkers. In this regard, anti-VEGF plus ICI combination therapy offers substantial synergistic potential in GI malignancies. Future progress will depend on biomarker-driven patient selection, refined sequencing and dosing strategies, and rationally designed multi-modal regimens to maximize therapeutic benefit while minimizing harm.

PMID 42467392
Read full article →
PubMedCureus2026-07-17

Exceptional Long-Term Disease Stability Under Nivolumab in Recurrent High-Grade Glioma: A Case Report.

Santos Joana N JN, Batista Francisca S FS, Sanches Frederico F, Miranda Ana A et al.

Immune checkpoint inhibitors have not demonstrated a survival benefit in unselected high-grade glioma populations; however, a subset of patients may achieve durable disease control. We report the case of a 30-year-old male patient diagnosed with a right temporoparietal high-grade glioma, initially classified as anaplastic astrocytoma and later evolving to astrocytoma, isocitrate dehydrogenase (IDH)-mutant, grade 4 according to the 2021 World Health Organization classification. The patient underwent multiple surgical resections followed by radiotherapy with concomitant temozolomide and subsequent adjuvant temozolomide (Stupp protocol). Upon disease recurrence, he received second-line treatment with lomustine plus bevacizumab, with documented progression across successive lines of therapy. In the absence of standard therapeutic options, off-label nivolumab was initiated in November 2018 following further progression. The tumor harbored an IDH1 R132H mutation and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation. Corticosteroids were discontinued prior to immunotherapy initiation. Serial magnetic resonance imaging demonstrated sustained radiological stability, without evidence of nodular enhancement or increased perfusion suggestive of recurrence. The most recent imaging assessment (March 2026) confirmed ongoing disease stability of more than seven years after treatment initiation. Treatment was well tolerated, with only mild immune-related arthralgias reported. The patient remains functionally independent, with stable mild residual hemiparesis. This case highlights the potential for prolonged disease stability under anti-Programmed cell death protein 1 (PD-1) therapy in selected patients with high-grade glioma. Although immunotherapy has not shown benefit in unselected populations, molecular features such as IDH mutation and MGMT promoter methylation, as well as the absence of corticosteroid use, may contribute to enhanced treatment responsiveness and warrant further investigation.

PMID 42465174
Read full article →
PubMedFrontiers in oncology2026-07-16

Survival outcomes of low-dose and high-dose bevacizumab front-line maintenance in advanced high-grade serous ovarian cancer: a propensity score-matched real-world study.

Wu Tao T, Shen Yahui Y, Wang Xiaowei X, Xi Ruxing R et al.

The optimal dose of bevacizumab for first-line maintenance therapy in advanced ovarian high-grade serous carcinoma (HGSC) remains controversial due to the lack of head-to-head RCTs. This real-world study aimed to compare the efficacy and safety of low-dose (7.5 mg/kg every 3 weeks) and high-dose (15 mg/kg every 3 weeks) bevacizumab in this population. We retrospectively analyzed patients with FIGO stage III-IV HGSC who received first-line bevacizumab maintenance therapy between January 2018 and May 2025. To control for confounding, 1:1 propensity score matching (PSM) was performed with sensitivity analyzes varying matching variables and caliper widths. Inverse probability of treatment weighting (IPTW) was used to confirm robustness. Post-hoc power analysis was performed The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS) and safety. Of 964 screened, 323 were eligible (low dose 179, high dose 144); after 1:1 PSM, 258 patients were matched (129/129) with standardized differences <0.1.After matching, PFS (HR 1.11, 95% CI 0.85-1.43, P = 0.450) and OS (HR 1.07, 95% CI 0.76-1.50, P = 0.688) did not differ significantly. IPTW analysis confirmed these findings (PFS: HR 1.06, P = 0.608; OS: HR 0.99, P = 0.942). Post-hoc power was 12% for the observed PFS HR of 1.11; the minimum detectable HR was 1.45 at 80% power. Prognostic analysis identified FIGO IV, non-complete resection (non-R0) residual disease, presence of ascites, BRCA-negative/unknown status, pre-maintenance CA125 ≥35 U/mL, and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) as independent adverse factors; bevacizumab dose was not prognostic. Safety was comparable; proteinuria trended lower with low dose (6.98% vs 12.40%, P = 0.147), hypertension was similar, and no gastrointestinal perforations or treatment-related deaths occurred. Sensitivity analyzes were consistent. In patients with advanced ovarian HGSC, low-dose and high-dose bevacizumab first line maintenance showed no statistically significant difference in PFS or OS, with a favorable safety signal for the low dose regimen. However, the study was underpowered to confirm equivalence, and a clinically meaningful increase in progression risk cannot be excluded. These findings support the feasibility of low-dose bevacizumab as a first-line maintenance option, pending prospective validation.

PMID 42459309
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about bevacizumab